Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer

被引：0
|
作者：
Gotoh, A [1 ]
Terao, S [1 ]
Shirakawa, T [1 ]
机构：
[1] Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Kobe, Hyogo 6500017, Japan
来源：
JOURNAL OF GENE MEDICINE | 2006年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [21] A Phase II Trial of Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST) in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer
    Ng, K.
    Sarker, S. -J.
    Greenwood, M.
    Gjafa, E.
    Alifrangis, C.
    Shamash, J.
    CLINICAL ONCOLOGY, 2019, 31 (02) : E23 - E24
  • [22] Phase II Trial of SBRT and Hormone Therapy for Oligometastases in Prostate Cancer
    Conde-Moreno, A. J.
    Lopez, F.
    Hervas, A.
    Piquer Camanes, T.
    Mendez, A.
    Puertas, M. D. M.
    Valero, J. J.
    Gomez Iturriaga, A.
    Rico, M.
    Vazquez de la Torre, M. L.
    Samper Ots, P. M.
    Perez Romasanta, L. A.
    Pastor Peidro, J.
    Ibanez, C.
    Ferrer, F.
    Porras-Martinez, M.
    Zapatero, A.
    Garcia Blanco, A. S.
    Rodriguez, A.
    Ferrer, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S149 - S150
  • [23] A phase I/II gene therapy trial in metastatic melanoma patients
    Adamina, Michel
    Weber, Walter P.
    Rosenthal, Rachel
    Schumacher, Reto
    Zajac, Paul
    Marti, Walter R.
    Huegli, Rolf
    Oertli, Daniel
    Spagnoli, Giulio
    Heberer, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (03) : S83 - S83
  • [24] Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial
    Catherine Van Poznak
    Andrew D. Seidman
    Marcus M. Reidenberg
    Mark M. Moasser
    Nancy Sklarin
    Kimberly Van Zee
    Patrick Borgen
    Marc Gollub
    Doreen Bacotti
    T-J Yao
    Renny Bloch
    Monica Ligueros
    Martin Sonenberg
    Larry Norton
    Clifford Hudis
    Breast Cancer Research and Treatment, 2001, 66 : 239 - 248
  • [25] Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial
    Van Poznak, C
    Seidman, AD
    Reidenberg, MM
    Moasser, MM
    Sklarin, N
    Van Zee, K
    Borgen, P
    Gollub, M
    Bacotti, D
    Yao, TJ
    Bloch, R
    Ligueros, M
    Sonenberg, M
    Norton, L
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 66 (03) : 239 - 248
  • [26] Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
    Dreicer, R.
    Garcia, J.
    Smith, S.
    Elson, P.
    Triozzi, P.
    Hodnick, S.
    Rini, B.
    Klein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: A multicenter phase II trial in Japan
    Naito, S.
    Tsukamoto, T.
    Koga, H.
    Harabayashi, T.
    Sumiyoshi, Y.
    Hoshi, S.
    Akaza, H.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (05) : 365 - 372
  • [28] A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
    Heath, Elisabeth I.
    Hillman, David W.
    Vaishampayan, Ulka
    Sheng, Shijie
    Sarkar, Fazlul
    Harper, Felicity
    Gaskins, Melvin
    Pitot, Henry C.
    Tan, Winston
    Ivy, S. Percy
    Pili, Roberto
    Carducci, Michael A.
    Erlichman, Charles
    Liu, Glenn
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7940 - 7946
  • [29] Phase II trial evaluating concomitant docetaxel and samarium (TAXAM) in patients with hormone refractory metastatic prostate cancer.
    Widmark, A
    Modig, H
    Johansson, M
    Franzen, L
    Johansson, L
    Turesson, I
    Laurell, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [30] Weekly epidoxorubicin therapy in hormone - Refractory metastatic prostate cancer
    Neri, B
    Barbagli, G
    Bellesi, P
    Di Loro, R
    Lombardi, V
    Lombardo, C
    Magrini, T
    Mottola, A
    Nicita, G
    Palminteri, E
    Ponchietti, R
    Raugei, A
    Intini, C
    ANTICANCER RESEARCH, 1997, 17 (5B) : 3817 - 3820
12345